Cyclacel Pharmaceuticals (CYCC) Short Interest Ratio & Short Volume $0.30 -0.01 (-2.17%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$0.30 +0.01 (+2.36%) As of 03/14/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Cyclacel Pharmaceuticals Short Interest DataCyclacel Pharmaceuticals (CYCC) has a short interest of 182,800 shares, representing 2.15% of the float (the number of shares available for trading by the public). This marks a 71.64% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 1.21 million shares to cover all short positions.Current Short Interest182,800 sharesPrevious Short Interest106,500 sharesChange Vs. Previous Month+71.64%Dollar Volume Sold Short$60,598.20Short Interest Ratio0.1 Days to CoverLast Record DateFebruary 28, 2025Outstanding Shares6,287,000 sharesFloat Size8,500,000 sharesShort Percent of Float2.15%Today's Trading Volume92,544 sharesAverage Trading Volume1,205,325 sharesToday's Volume Vs. Average8% Short Selling Cyclacel Pharmaceuticals? Sign up to receive the latest short interest report for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCYCC Short Interest Over TimeCYCC Days to Cover Over TimeCYCC Percentage of Float Shorted Over Time Remove Ads Cyclacel Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/28/2025182,800 shares $60,598.20 +71.6%2.2%0.1 $0.33 2/15/2025106,500 shares $39,586.05 -43.4%1.3%0 $0.37 1/31/2025188,200 shares $62,670.60 -36.4%1.7%0.1 $0.33 1/15/2025295,900 shares $109,483.00 +119.8%2.7%0.1 $0.37 12/31/2024134,600 shares $50,609.60 +102.7%2.2%0 $0.38 12/15/202466,400 shares $23,977.04 -64.6%1.1%0 $0.36 11/30/2024187,700 shares $76,957.00 -72.1%3.1%0.1 $0.41 11/15/2024672,100 shares $251,365.40 +906.1%11.1%0.5 $0.37 10/31/202466,800 shares $43,353.20 +83.0%3.3%0.1 $0.65 10/15/202436,500 shares $31,390.00 -23.8%1.8%0 $0.86 Get the Latest News and Ratings for CYCC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 9/30/202447,900 shares $47,421.00 +0.6%2.5%0.8 $0.99 9/15/202447,600 shares $48,076.00 -14.9%2.5%0.7 $1.01 8/31/202455,900 shares $58,806.80 +3.0%3.0%0.7 $1.05 8/15/202454,300 shares $71,676.00 -18.6%2.9%0.4 $1.32 7/31/202466,700 shares $112,056.00 -41.0%4.9%0.5 $1.68 7/15/2024113,100 shares $196,794.00 -32.4%8.3%0.1 $1.74 6/30/2024167,300 shares $271,026.00 +8.1%12.2%0.2 $1.62 6/15/2024154,700 shares $261,443.00 +63.7%11.3%0.2 $1.69 5/31/202494,500 shares $249,480.00 -35.0%6.9%0.1 $2.64 5/15/2024145,300 shares $354,532.00 -58.6%10.6%0.2 $2.44 4/30/2024351,100 shares $744,332.00 +814.3%29.3%0.5 $2.12 4/15/202438,400 shares $60,672.00 +58.0%3.2%0.8 $1.58 3/31/202424,300 shares $51,270.57 -8.7%2.0%0.2 $2.11 3/15/202426,600 shares $64,638.00 -35.9%2.2%0.2 $2.43 2/29/202441,500 shares $106,240.00 -44.5%3.6%0.2 $2.56 2/15/202474,800 shares $198,968.00 -10.0%6.4%0.5 $2.66 1/31/202483,100 shares $186,144.00 +0.7%9.3%0.5 $2.24 1/15/202482,500 shares $194,700.00 +129.2%9.1%0.6 $2.36 12/31/202336,000 shares $96,120.00 -13.3%4.0%0.3 $2.67 12/15/202341,500 shares $148,466.25 -92.2%5.9%1.3 $3.58 11/30/2023530,900 shares $159,270.00 +2.5%5.0%3 $0.30 11/15/2023518,200 shares $179,297.20 +1.2%4.9%3.6 $0.35 10/31/2023512,300 shares $275,924.78 +1.1%4.8%4.1 $0.54 10/15/2023506,900 shares $316,305.60 +3.7%4.7%4.3 $0.62 9/30/2023488,800 shares $173,377.36 +7.1%4.5%5.2 $0.35 9/15/2023456,600 shares $148,349.34 +7.0%4.2%4.9 $0.32 8/31/2023426,900 shares $169,052.40 +4.9%4.0%4.3 $0.40 8/15/2023406,800 shares $190,382.40 -7.6%3.8%5.4 $0.47 7/31/2023440,100 shares $294,426.90 -0.5%4.1%6.3 $0.67 7/15/2023442,100 shares $259,114.81 +1.5%4.1%6.1 $0.59Jeff Brown's Urgent March 17th Alert (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. 6/30/2023435,400 shares $256,494.14 -1.8%4.0%7.7 $0.59 6/15/2023443,400 shares $297,477.06 -12.7%4.1%7.5 $0.67 5/31/2023508,000 shares $325,120.00 +5.5%4.7%9.9 $0.64 5/15/2023481,400 shares $260,629.96 No Change4.4%8.1 $0.54 10/31/2022461,800 shares $641,902.00 +15.6%N/A0.9 $1.39 10/15/2022399,400 shares $519,220.00 -15.6%N/A0.6 $1.30 9/30/2022473,000 shares $690,580.00 +16.7%N/A0.5 $1.46 9/15/2022405,500 shares $640,690.00 -44.1%N/A0.4 $1.58 8/31/2022725,400 shares $1.22 million -43.8%N/A0.6 $1.68 8/15/20221,290,000 shares $2.04 million +50.6%N/A1.1 $1.58 7/31/2022856,400 shares $976,296.00 +46.7%N/A1.1 $1.14 7/15/2022583,900 shares $712,358.00 +147.5%N/A0.9 $1.22 6/30/2022235,900 shares $254,772.00 -5.5%2.6%0.5 $1.08 6/15/2022249,500 shares $279,440.00 +10.0%2.8%0.9 $1.12 5/31/2022226,800 shares $272,160.00 -18.6%2.8%1.1 $1.20 5/15/2022278,500 shares $387,115.00 -23.9%3.4%2.1 $1.39 4/30/2022366,100 shares $684,607.00 -21.0%4.5%3 $1.87 4/15/2022463,600 shares $950,380.00 +53.4%5.7%3.7 $2.05 3/31/2022302,200 shares $921,710.00 -5.1%N/A7.2 $3.05 3/15/2022318,500 shares $863,135.00 -4.7%3.9%4.9 $2.71 2/28/2022334,100 shares $1.09 million -5.8%4.1%4.6 $3.25 2/15/2022354,500 shares $1.31 million -11.7%4.3%4.3 $3.69 1/31/2022401,300 shares $1.28 million -3.2%4.9%4.4 $3.18 1/15/2022414,400 shares $1.50 million +17.1%5.1%4.6 $3.62 12/31/2021353,800 shares $1.38 million -3.4%4.3%3.8 $3.89 12/15/2021366,200 shares $1.23 million -14.1%4.5%3.5 $3.36 11/30/2021426,100 shares $1.53 million -12.7%5.3%3.8 $3.58 11/15/2021488,300 shares $2.33 million -4.0%6.1%4.2 $4.78 10/29/2021508,600 shares $2.50 million -0.6%6.8%4.4 $4.91 10/15/2021511,600 shares $2.85 million -2.2%6.9%4.2 $5.57 9/30/2021523,300 shares $2.76 million +3.1%7.0%4.2 $5.27 9/15/2021507,400 shares $3.00 million +6.4%6.8%5.1 $5.91 8/31/2021476,800 shares $2.59 million -2.5%6.4%5.4 $5.44 8/13/2021488,800 shares $2.40 million -14.8%6.6%5.7 $4.90 7/30/2021573,900 shares $2.85 million -20.0%7.7%6 $4.96 7/15/2021717,600 shares $3.79 million -9.9%9.7%6.4 $5.28 6/30/2021796,400 shares $4.71 million +22.1%10.7%6.7 $5.92 6/15/2021652,200 shares $4.36 million -26.7%8.8%4.9 $6.69 5/28/2021890,200 shares $6.38 million +3.1%12.0%4.6 $7.17 5/14/2021863,800 shares $5.67 million +5.2%12.0%3.2 $6.56 4/30/2021821,000 shares $5.84 million -4.1%11.4%1.6 $7.11 4/15/2021856,300 shares $6.02 million -0.2%N/A0 $7.03 3/31/2021858,100 shares $5.73 million -11.3%13.6%1.2 $6.68 3/15/2021967,900 shares $7.31 million -7.8%15.4%1 $7.55 2/26/20211,050,000 shares $7.35 million +1.9%29.2%1.2 $7.00 2/12/20211,030,000 shares $9.98 million +26.4%28.6%1.2 $9.69 1/29/2021814,600 shares $6.19 million -16.2%16.2%1.1 $7.60 1/15/2021972,300 shares $8.76 million +9.6%19.3%2.2 $9.01 12/31/2020887,400 shares $6.34 million +319.2%17.7%2.1 $7.15 12/15/2020211,700 shares $908,193.00 +221.7%4.0%0.6 $4.29The real reason gold is soaring (and likely to continue) (Ad)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driving a hidden gold market boom. Garrett Goggin, a renowned precious metals expert with 20+ years of experience, reveals 5 explosive investment opportunities set to explode in this new era. Backed by triple-digit returns in 2024, Garrett’s insights show you how to position yourself for wealth in 2025. Don’t wait—these opportunities can disappear fast!Discover Garrett’s highly sought-after gold insights and seize this opportunity before it’s gone. 11/30/202065,800 shares $253,330.00 -9.5%1.4%0.4 $3.85 11/15/202072,700 shares $257,358.00 -16.1%1.5%0.6 $3.54 10/30/202086,600 shares $296,172.00 +166.5%1.8%0.5 $3.42 10/15/202032,500 shares $134,062.50 -39.3%0.7%0.2 $4.13 9/30/202053,500 shares $195,275.00 +87.1%1.1%0.2 $3.65 9/15/202028,600 shares $98,670.00 -2.7%0.6%0.1 $3.45 8/31/202029,400 shares $112,308.00 -84.9%0.6%0.1 $3.82 8/14/2020194,300 shares $872,407.00 +50.9%4.0%0.6 $4.49 7/31/2020128,800 shares $637,560.00 -38.2%2.7%0.2 $4.95 7/15/2020208,500 shares $925,740.00 -10.8%4.3%0.3 $4.44 6/30/2020233,800 shares $1.08 million +6.1%4.9%0.3 $4.64 6/15/2020220,400 shares $996,208.00 -35.6%4.6%0.3 $4.52 5/29/2020342,200 shares $1.85 million +295.2%7.1%0.4 $5.40 5/15/202086,600 shares $355,926.00 -30.9%1.8%0.1 $4.11 4/30/2020125,400 shares $522,918.00 +1,040.0%15.1%0.3 $4.17 4/15/202011,000 shares $87,670.00 -92.2%1.3%0 $7.97 3/31/2020141,700 shares $569,634.00 +243.1%0.8%0.8 $4.02 CYCC Short Interest - Frequently Asked Questions What is Cyclacel Pharmaceuticals' current short interest? Short interest is the volume of Cyclacel Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of February 28th, investors have sold 182,800 shares of CYCC short. 2.15% of Cyclacel Pharmaceuticals' shares are currently sold short. Learn More on Cyclacel Pharmaceuticals' current short interest. Which institutional investors are shorting Cyclacel Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cyclacel Pharmaceuticals: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Cyclacel Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.15% of Cyclacel Pharmaceuticals' floating shares are currently sold short. Is Cyclacel Pharmaceuticals' short interest increasing or decreasing? Cyclacel Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 182,800 shares, an increase of 71.6% from the previous total of 106,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Cyclacel Pharmaceuticals' float size? Cyclacel Pharmaceuticals currently has issued a total of 6,287,000 shares. Some of Cyclacel Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cyclacel Pharmaceuticals currently has a public float of 8,500,000 shares. How does Cyclacel Pharmaceuticals' short interest compare to its competitors? 2.15% of Cyclacel Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Cyclacel Pharmaceuticals: Hoth Therapeutics, Inc. (1.34%), Cyclerion Therapeutics, Inc. (6.54%), Organovo Holdings, Inc. (9.33%), Omega Therapeutics, Inc. (26.99%), Biofrontera Inc. (1.11%), Creative Medical Technology Holdings, Inc. (10.81%), Ainos, Inc. (4.93%), Ensysce Biosciences, Inc. (3.23%), NLS Pharmaceutics Ltd. (3.71%), Avalon GloboCare Corp. (10.71%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($23.74 billion), iShares 20+ Year Treasury Bond ETF ($10.75 billion), MicroStrategy Incorporated ($6.56 billion), Apollo Global Management, Inc. ($5.40 billion), Charter Communications, Inc. ($4.57 billion), AppLovin Co. ($4.45 billion), Capital One Financial Co. ($4.33 billion), Super Micro Computer, Inc. ($4.23 billion), Schlumberger Limited ($3.22 billion), and Royal Caribbean Cruises Ltd. ($3.06 billion). View all of the most shorted stocks. What does it mean to sell short Cyclacel Pharmaceuticals stock? Short selling CYCC is an investing strategy that aims to generate trading profit from Cyclacel Pharmaceuticals as its price is falling. CYCC shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cyclacel Pharmaceuticals? A short squeeze for Cyclacel Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CYCC, which in turn drives the price of the stock up even further. How often is Cyclacel Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CYCC, twice per month. The most recent reporting period available is February, 28 2025. More Short Interest Resources from MarketBeat Related Companies Hoth Therapeutics Short Interest Data Cyclerion Therapeutics Short Interest Data Organovo Short Interest Data Omega Therapeutics Short Interest Data Biofrontera Short Interest Data Creative Medical Technology Short Interest Data Ainos Short Interest Data Ensysce Biosciences Short Interest Data NLS Pharmaceutics Short Interest Data Avalon GloboCare Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CYCC) was last updated on 3/15/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYCC Stock Alerts